These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 16080466)
41. [A case of secondary malignant lymphoma of the urinary bladder]. Yokoyama M; Kobayashi T; Kubo Y; Kageyama Y; Kihara K Hinyokika Kiyo; 2006 Apr; 52(4):285-7. PubMed ID: 16686357 [TBL] [Abstract][Full Text] [Related]
42. Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder. Nascimento AF; Winters GL; Pinkus GS Am J Surg Pathol; 2007 Sep; 31(9):1344-50. PubMed ID: 17721189 [TBL] [Abstract][Full Text] [Related]
43. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935 [TBL] [Abstract][Full Text] [Related]
44. Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma. Tholstrup D; de Nully Brown P; Jurlander J; Hansen M Eur J Haematol; 2007 Aug; 79(2):100-6. PubMed ID: 17608712 [TBL] [Abstract][Full Text] [Related]
45. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. Ghesquières H; Berger F; Felman P; Callet-Bauchu E; Bryon PA; Traverse-Glehen A; Thieblemont C; Baseggio L; Michallet AS; Coiffier B; Salles G J Clin Oncol; 2006 Nov; 24(33):5234-41. PubMed ID: 17043351 [TBL] [Abstract][Full Text] [Related]
46. [Carcinoembryonic antigen as an indicator of the effectiveness of the chemotherapy of malignant tumors]. Tkacheva GA; Moroz LV; Polevaia EB; Ozherel'ev AS; Ausekar BV Vestn Akad Med Nauk SSSR; 1986; (5):41-5. PubMed ID: 3014776 [No Abstract] [Full Text] [Related]
47. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis. Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110 [TBL] [Abstract][Full Text] [Related]
49. Disseminated intravascular B-cell lymphoma: clinicopathological features and outcome of three cases treated with anthracycline-based immunochemotherapy. Bouzani M; Karmiris T; Rontogianni D; Delimpassi S; Apostolidis J; Mpakiri M; Nikiforakis E Oncologist; 2006 Sep; 11(8):923-8. PubMed ID: 16951396 [TBL] [Abstract][Full Text] [Related]
50. Primary diffuse large B-cell lymphoma of the stomach. Ferreri AJ; Montalbán C Crit Rev Oncol Hematol; 2007 Jul; 63(1):65-71. PubMed ID: 17339119 [TBL] [Abstract][Full Text] [Related]
51. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer. Idelevich E; Karminsky N; Dinerman M; Katsenelson RL; Zvi NB; Baruch NB; Biran H; Man S; Shani A Acta Oncol; 2007; 46(3):324-9. PubMed ID: 17450467 [TBL] [Abstract][Full Text] [Related]
52. A diagnosis dilemma of back pain in non-Hodgkin lymphoma. Cheung W; Maksymiuk A Pediatr Blood Cancer; 2005 Jan; 44(1):100-1. PubMed ID: 15459962 [No Abstract] [Full Text] [Related]
53. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. Besson C; Canioni D; Lepage E; Pol S; Morel P; Lederlin P; Van Hoof A; Tilly H; Gaulard P; Coiffier B; Gisselbrecht C; Brousse N; Reyes F; Hermine O; J Clin Oncol; 2006 Feb; 24(6):953-60. PubMed ID: 16418500 [TBL] [Abstract][Full Text] [Related]
54. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma. Gong Y; Ren L; Zhou L; Zhu J; Huang M; Zhou X; Wang J; Lu Y; Hou M; Wei Y Cancer Chemother Pharmacol; 2009 Jul; 64(2):327-33. PubMed ID: 19048253 [TBL] [Abstract][Full Text] [Related]
55. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450 [TBL] [Abstract][Full Text] [Related]
56. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy. Jessen C; Agerbaek M; Von Der Maase H Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018 [TBL] [Abstract][Full Text] [Related]
57. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Young RH Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813 [TBL] [Abstract][Full Text] [Related]
58. [Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region]. Paviot BT; Bachelot T; Clavreul G; Jacquin JP; Mille D; Rodrigues JM Bull Cancer; 2009 Oct; 96(10):929-40. PubMed ID: 19696006 [TBL] [Abstract][Full Text] [Related]
59. [The modified program NHL-BFM-90 in the treatment of patients with diffuse large B-cell lymphosarcoma]. Magomedova AU; Kravchenko SK; Kremenetskaia AM; Zvonkov EE; Bariakh EA; Margolin OV; Kaplanskaia IB; Vorob'ev IA; Samoĭlova RS; Obukhova TN; Moiseeva TN; Zybunova EE; Gemdzhian EG; Vorob'ev AI Ter Arkh; 2006; 78(10):44-7. PubMed ID: 17180937 [TBL] [Abstract][Full Text] [Related]
60. Primary breast lymphoma: case reports and review of the literature. Sanguinetti A; Ragusa M; Lucchini R; Monacelli M; Calzolari F; Misso C; Avenia N G Chir; 2008 May; 29(5):230-2. PubMed ID: 18507958 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]